Studies how aldosterone, a hormone, relates to high blood pressure
Observes adults with high blood pressure to learn about the hormone aldosterone.
Plain-language title generated from the registry record
Registry title: REFOCUS-HTN US-WEST: A Data Infrastructure to Characterize Individuals With Hypertension
Key facts
- Where
- Oakland, United StatesSee the site
Where in United States
- Kaiser Permanente Northern CaliforniaOakland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kaiser Permanente
- Trial code
- NCT07780500
- Record updated
- 5 October 2026
- Original description
The goal of the REFOCUS-HTN US-WEST program is to gain a better understanding of the role of a hormone called aldosterone in the development of hypertension. The SCALED sub-study is an observational cohort study that will enroll from REFOCUS-HTN cohort for prospective data collection.Read full original descriptionShow less
REFOCUS-HTN US-WEST: a Data Infrastructure to Characterize Contemporary Individuals With Hypertension, Their Care, Health Outcomes, and Wellbeing
The goal of the REFOCUS-HTN US-WEST program is to gain a better understanding of the role of a hormone called aldosterone in the development of hypertension. The SCALED sub-study is an observational cohort study that will enroll from REFOCUS-HTN cohort for prospective data collection.
Inclusion: The SCALED Cohort will be identified from the REFOCUS-HTN Cohort which includes men and women ≥ 18 years of age with established hypertension in the KPNC EHR from January 2012 through March 31, 2029. Established hypertension will be defined as one of the following:; ≥1 outpatient, non-emergency department diagnosis of hypertension; ≥2 consecutive outpatient measures of systolic blood pressure ≥130 mmHg at least 90 days apart; ≥2 consecutive outpatient measures of diastolic blood pressure ≥80 mmHg at least 90 days apart; Additional Eligibility Criteria for SCALED:; Hypertension diagnosis within the past 18 months prior to screening; At least 6 months of continuous health plan coverage prior to initial visit.
Exclusion: Bariatric surgery or GLP1 prescription in the last 12 months; Exposure to an aldosterone synthase inhibitor or a mineralocorticoid receptor antagonist in the last 12 weeks; Kidney transplant; Currently receiving dialysis; Diagnosed cause of secondary hypertension from drug or alcohol induced, or renovascular hypertension; Last known estimated glomerular filtration rate < 45 mL/min/1.73m2 (according to the CKD-EPI equation) at the time of screening; Current enrollment in any cardiovascular or blood pressure interventional trial.